Free Trial

Brainstorm Cell Therapeutics (BCLI) Short Interest Ratio & Short Volume

Brainstorm Cell Therapeutics logo
$1.14 -0.03 (-2.56%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.15 +0.01 (+1.23%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Short Interest Data

Brainstorm Cell Therapeutics (BCLI) has a short interest of 463,300 shares, representing 7.51% of the float (the number of shares available for trading by the public). This marks a -13.71% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 388,376 shares to cover all short positions.

Current Short Interest
463,300 shares
Previous Short Interest
536,900 shares
Change Vs. Previous Month
-13.71%
Dollar Volume Sold Short
$509.63 thousand
Short Interest Ratio
0.4 Days to Cover
Last Record Date
June 15, 2025
Outstanding Shares
9,840,000 shares
Float Size
6,170,000 shares
Short Percent of Float
7.51%
Today's Trading Volume
98,008 shares
Average Trading Volume
388,376 shares
Today's Volume Vs. Average
25%
Short Selling Brainstorm Cell Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

BCLI Short Interest Over Time

BCLI Days to Cover Over Time

BCLI Percentage of Float Shorted Over Time

Brainstorm Cell Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/15/2025463,300 shares $509.63 thousand -13.7%7.5%0.4 $1.10
5/31/2025536,900 shares $617.33 thousand +156.3%8.7%0.4 $1.15
5/15/2025209,500 shares $243.02 thousand -28.1%3.4%0.2 $1.16
4/30/2025291,400 shares $378.82 thousand -16.0%5.2%1.8 $1.30
4/15/2025346,700 shares $269.73 thousand +152.7%6.8%2.5 $0.78
3/31/2025137,200 shares $172.87 thousand +11.7%2.7%3.3 $1.26
3/15/2025122,800 shares $195.25 thousand +14.6%2.8%2 $1.59
2/28/2025107,200 shares $171.52 thousand -3.3%2.4%1.6 $1.60
2/15/2025110,900 shares $206.27 thousand +21.3%2.5%1.4 $1.86
1/31/202591,400 shares $166.35 thousand -47.2%2.1%0.9 $1.82
1/15/2025173,000 shares $354.65 thousand +85.4%3.9%1.7 $2.05
12/31/202493,300 shares $211.79 thousand -38.8%2.1%0.8 $2.27
12/15/2024152,400 shares $220.98 thousand +2.8%3.1%1.4 $1.45
11/30/2024148,200 shares $257.87 thousand -14.8%3.0%1.6 $1.74
11/15/2024173,900 shares $210.42 thousand +58.4%3.6%2.3 $1.21
10/31/2024109,800 shares $205.33 thousand -33.8%2.3%1.7 $1.87
10/15/2024165,900 shares $351.71 thousand +33.2%3.4%3.6 $2.12
9/30/2024124,600 shares $28.70 thousand -91.1%2.6%3.6 $0.23
9/15/20241,400,000 shares $394.80 thousand +8.5%N/A3.2 $0.28
8/31/20241,290,000 shares $398.61 thousand -20.4%N/A2.4 $0.31
8/15/20241,620,000 shares $507.38 thousand +51.4%N/A2.9 $0.31
7/31/20241,070,000 shares $366.15 thousand -0.9%N/A1.9 $0.34
7/15/20241,080,000 shares $450.36 thousand -26.5%N/A1.8 $0.42
6/30/20241,470,000 shares $497.60 thousand +65.1%N/A1.9 $0.34
6/15/2024890,600 shares $418.58 thousand -20.5%N/A1 $0.47
5/31/20241,120,000 shares $544.99 thousand -20.6%N/A1.2 $0.49
5/15/20241,410,000 shares $682.44 thousand -32.9%N/A1.4 $0.48
4/30/20242,100,000 shares $792.75 thousand +5.5%N/A2.1 $0.38
4/15/20241,990,000 shares $1.09 million +48.5%N/A2 $0.55
3/31/20241,340,000 shares $756.70 thousand +57.6%N/A1.3 $0.56
3/15/2024850,300 shares $283.06 thousand -20.5%N/A0.6 $0.33
2/29/20241,070,000 shares $392.69 thousand -13.0%N/A0.7 $0.37
2/15/20241,230,000 shares $477.24 thousand -39.4%N/A0.5 $0.39
1/31/20242,030,000 shares $717.20 thousand -15.1%N/A0.8 $0.35
1/15/20242,390,000 shares $781.29 thousand -43.2%N/A0.9 $0.33
12/31/20234,210,000 shares $1.15 million +25.3%N/A1.5 $0.27
12/15/20233,360,000 shares $789.60 thousand -4.0%N/A0.9 $0.24
11/30/20233,500,000 shares $976.50 thousand -7.2%N/A1.1 $0.28
11/15/20233,770,000 shares $689.91 thousand +5.6%N/A1.6 $0.18
10/31/20233,570,000 shares $546.21 thousand -20.5%9.8%1.9 $0.15
The Trump Dump is starting; Get out of stocks now? (Ad)

The first 365 days of the Trump presidency… Will be the best time to get rich in American history.

If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a
10/15/20234,490,000 shares $763.30 thousand +1.1%12.4%2.6 $0.17
9/30/20234,440,000 shares $888.44 thousand +26.1%12.2%3 $0.20
9/15/20233,520,000 shares $3.39 million +9.3%9.7%9.3 $0.96
8/31/20233,220,000 shares $5.51 million +21.1%9.2%13.4 $1.71
8/15/20232,660,000 shares $4.15 million No Change7.6%11.3 $1.56
7/31/20232,660,000 shares $4.89 million -5.3%8.6%12 $1.84
7/15/20232,810,000 shares $5.54 million +0.4%9.1%12.1 $1.97
6/30/20232,800,000 shares $5.77 million +2.9%9.1%11.7 $2.06
6/15/20232,720,000 shares $7.37 million -5.6%8.8%6.7 $2.71
5/31/20232,880,000 shares $8.21 million +0.4%9.6%7.2 $2.85
5/15/20232,870,000 shares $7.92 million -9.2%9.5%8 $2.76
4/30/20233,160,000 shares $9.13 million +7.9%11.3%7.8 $2.89
4/15/20232,930,000 shares $8.23 million -5.5%10.4%7.3 $2.81
3/31/20233,100,000 shares $10.23 million +29.7%11.0%7.7 $3.30
3/15/20232,390,000 shares $3.87 million +0.8%8.5%10.2 $1.62
2/28/20232,370,000 shares $5.36 million +3.0%8.4%10.6 $2.26
2/15/20232,300,000 shares $5.24 million +18.6%8.1%9.6 $2.28
1/31/20231,940,000 shares $3.53 million -1.5%6.9%7 $1.82
1/15/20231,970,000 shares $2.88 million -3.9%7.0%8.3 $1.46
12/30/20222,050,000 shares $3.36 million -9.3%7.3%8.9 $1.64
12/15/20222,260,000 shares $4.09 million No Change8.0%9.6 $1.81
11/30/20222,260,000 shares $3.73 million -12.4%8.0%8.8 $1.65
11/15/20222,580,000 shares $4.46 million -4.1%9.1%9.8 $1.73
10/31/20222,690,000 shares $9.58 million +10.3%9.5%11.1 $3.56
10/15/20222,440,000 shares $8.49 million +23.2%8.7%10.2 $3.48
9/30/20221,980,000 shares $8.75 million +52.3%7.0%8.9 $4.42
9/15/20221,300,000 shares $5.59 million +68.2%4.6%7.2 $4.30
8/31/2022772,900 shares $2.80 million +36.6%2.7%5.3 $3.62
8/15/2022565,900 shares $1.95 million -5.4%2.0%4.8 $3.45
7/31/2022598,200 shares $1.53 million +3.1%2.1%9.8 $2.56
7/15/2022580,300 shares $1.53 million -9.5%3.2%9.5 $2.64
6/30/2022641,300 shares $1.77 million -0.1%3.6%10.7 $2.76
6/15/2022642,100 shares $1.83 million -4.9%3.6%10.2 $2.85
5/31/2022675,200 shares $1.99 million +5.6%2.4%10.6 $2.94
5/15/2022639,600 shares $1.74 million +6.6%2.3%9.7 $2.72
4/30/2022600,200 shares $1.80 million -2.1%2.1%9.1 $3.00
4/15/2022612,800 shares $1.93 million -8.5%2.2%8.6 $3.15
3/31/2022669,400 shares $2.25 million -8.4%2.4%8.4 $3.36
3/15/2022731,100 shares $2.30 million -0.6%2.6%5.1 $3.15
2/28/2022735,200 shares $2.24 million -7.0%2.6%2.4 $3.05
2/15/2022790,200 shares $2.47 million -22.5%2.8%2.1 $3.12
1/31/20221,020,000 shares $3.18 million -9.7%3.3%2.5 $3.12
1/15/20221,130,000 shares $4.01 million -17.5%3.6%2.7 $3.55
12/31/20211,370,000 shares $5.48 million +11.4%4.4%3.3 $4.00
12/15/20211,230,000 shares $4.05 million +32.1%3.9%3.3 $3.29
11/30/2021931,500 shares $3.54 million +27.1%3.1%4.2 $3.80
11/15/2021732,900 shares $2.23 million -1.4%2.4%4.8 $3.04
10/29/2021743,600 shares $2.16 million -11.5%2.5%6.3 $2.90
10/15/2021839,800 shares $2.59 million -14.4%2.8%5.9 $3.08
9/30/2021981,000 shares $3.24 million +6.8%3.3%6.6 $3.30
The Trump Dump is starting; Get out of stocks now? (Ad)

The first 365 days of the Trump presidency… Will be the best time to get rich in American history.

If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a
9/15/2021918,700 shares $3.24 million -11.7%3.1%4.1 $3.53
8/31/20211,040,000 shares $3.61 million No Change3.5%4.3 $3.47
8/13/20211,040,000 shares $3.83 million +16.3%3.5%3.5 $3.68
7/30/2021894,200 shares $3.60 million -32.3%3.0%2.7 $4.03
7/15/20211,320,000 shares $4.51 million -5.7%4.4%3.6 $3.42
6/30/20211,400,000 shares $5.32 million -60.9%4.7%3.4 $3.80
6/15/20213,580,000 shares $14.21 million +0.3%11.9%6.3 $3.97
5/28/20213,570,000 shares $12.78 million -18.5%11.9%5.8 $3.58
5/14/20214,380,000 shares $14.10 million +14.7%N/A6 $3.22
4/30/20213,820,000 shares $13.41 million +4.1%N/A4.4 $3.51
4/15/20213,670,000 shares $12.92 million -16.4%N/A3.2 $3.52
3/31/20214,390,000 shares $16.29 million +4.0%N/A3.8 $3.71
3/15/20214,220,000 shares $18.06 million +7.4%N/A3.5 $4.28
2/26/20213,930,000 shares $15.60 million -6.9%N/A3.4 $3.97
2/12/20214,220,000 shares $30.00 million -9.4%N/A3.2 $7.11
1/29/20214,660,000 shares $29.38 million -2.9%N/A3.1 $6.31
1/15/20214,800,000 shares $24.05 million -11.1%N/A3.6 $5.01
12/31/20205,400,000 shares $25.00 million -15.2%N/A4.1 $4.63
12/15/20206,370,000 shares $33.06 million -5.9%N/A4.9 $5.19
11/30/20206,770,000 shares $35.54 million +5.5%N/A5.7 $5.25
11/15/20206,420,000 shares $74.79 million +7.5%N/A6.1 $11.65
10/30/20205,970,000 shares $64.18 million +17.5%N/A10.2 $10.75
10/15/20205,080,000 shares $84.79 million +12.1%N/A8.4 $16.69
9/30/20204,530,000 shares $76.65 million +18.3%N/A8.7 $16.92
9/15/20203,830,000 shares $54.19 million -1.5%N/A6 $14.15
8/31/20203,890,000 shares $49.05 million +8.1%N/A5.5 $12.61
8/14/20203,600,000 shares $47.77 million +2.9%N/A4.8 $13.27
7/31/20203,500,000 shares $47.43 million -20.8%N/A4.8 $13.55
7/15/20204,420,000 shares $57.15 million No ChangeN/A6.3 $12.93

BCLI Short Interest - Frequently Asked Questions

What is Brainstorm Cell Therapeutics' current short interest?

Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 463,300 shares of BCLI short. 7.51% of Brainstorm Cell Therapeutics' shares are currently sold short. Learn More on Brainstorm Cell Therapeutics' current short interest.

What is a good short interest percentage for Brainstorm Cell Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.51% of Brainstorm Cell Therapeutics' floating shares are currently sold short.

Is Brainstorm Cell Therapeutics' short interest increasing or decreasing?

Brainstorm Cell Therapeutics saw a decline in short interest in June. As of June 15th, there was short interest totaling 463,300 shares, a decline of 13.7% from the previous total of 536,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Brainstorm Cell Therapeutics' float size?

Brainstorm Cell Therapeutics currently has issued a total of 9,840,000 shares. Some of Brainstorm Cell Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Brainstorm Cell Therapeutics currently has a public float of 6,170,000 shares.

How does Brainstorm Cell Therapeutics' short interest compare to its competitors?

7.51% of Brainstorm Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Brainstorm Cell Therapeutics: Aligos Therapeutics, Inc. (12.85%), Applied Therapeutics Inc. (15.31%), Actinium Pharmaceuticals, Inc. (4.88%), Mural Oncology PLC (1.66%), Annovis Bio, Inc. (14.32%), Scilex Holding Company (8.73%), Iterum Therapeutics PLC (2.99%), Pluri Inc. (0.71%), Shattuck Labs, Inc. (3.84%), ABVC BioPharma, Inc. (3.49%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks.

What does it mean to sell short Brainstorm Cell Therapeutics stock?

Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. BCLI shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Brainstorm Cell Therapeutics?

A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further.

How often is Brainstorm Cell Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is June, 15 2025.




This page (NASDAQ:BCLI) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners